Globe Newswire01.31.22
NeuroMetrix Inc. has added to its executive team with the appointment of Susan M. Bell as senior vice president, Population Health & Value Based Care.
"Sue's background in population health, and Medicare Advantage in particular, is ideally suited to our DPNCheck business. The technology already has initial adoption by some of the largest Medicare Advantage plans and we believe there is a substantial opportunity to grow and expand the business," said Shai N. Gozani M.D., Ph.D., NeuroMetrix president and CEO. "We are excited to have someone with Sue's deep experience and energy join at this time, particularly as we are gearing up to launch our second generation DPNCheck device. I look forward to working with Sue to build on our success to date and to take the DPNCheck business to new heights."
Bell has more than 20 years of sales, business development and strategy experience in the Medicare Advantage sector, and more generally in population health. She was most recently at eHealth Inc., where she was senior director, Value Based Provider Partnerships. In this role, she built partnerships with the largest and most innovative Medicare Advantage plans and at-risk provider networks. Before that, Bell was chief growth officer at Cecelia Health, where she built the company's chronic disease management business. Bell has also held senior roles at CareCentrix Inc., ZeOmega Inc., Bosch Healthcare, and VITAS Healthcare.
Bell earned a bachelor's degree in nursing from the University of Manitoba and is licensed as a registered nurse.
Bell is now responsible for growing the NeuroMetrix's DPNCheck business with a primary focus on the Medicare Advantage population, and more broadly, expanding the company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may lead to foot ulcers and amputation. It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor peripheral neuropathies.
NeuroMetrix develops and commercializes non-invasive medical devices to diagnose and treat pain and neurological disorders. The company has three commercial products. DPNCheck is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.
"Sue's background in population health, and Medicare Advantage in particular, is ideally suited to our DPNCheck business. The technology already has initial adoption by some of the largest Medicare Advantage plans and we believe there is a substantial opportunity to grow and expand the business," said Shai N. Gozani M.D., Ph.D., NeuroMetrix president and CEO. "We are excited to have someone with Sue's deep experience and energy join at this time, particularly as we are gearing up to launch our second generation DPNCheck device. I look forward to working with Sue to build on our success to date and to take the DPNCheck business to new heights."
Bell has more than 20 years of sales, business development and strategy experience in the Medicare Advantage sector, and more generally in population health. She was most recently at eHealth Inc., where she was senior director, Value Based Provider Partnerships. In this role, she built partnerships with the largest and most innovative Medicare Advantage plans and at-risk provider networks. Before that, Bell was chief growth officer at Cecelia Health, where she built the company's chronic disease management business. Bell has also held senior roles at CareCentrix Inc., ZeOmega Inc., Bosch Healthcare, and VITAS Healthcare.
Bell earned a bachelor's degree in nursing from the University of Manitoba and is licensed as a registered nurse.
Bell is now responsible for growing the NeuroMetrix's DPNCheck business with a primary focus on the Medicare Advantage population, and more broadly, expanding the company's footprint in the value-based healthcare market. DPNCheck is a widely used point-of-care test that provides physicians with fast, accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies. It is often used to stage the severity of Diabetic Peripheral Neuropathy (DPN), which is the most common specific cause of peripheral nerve disease and a ubiquitous long-term complication of diabetes that may lead to foot ulcers and amputation. It is designed to be used by clinicians at the point-of-care to objectively detect, stage, and monitor peripheral neuropathies.
NeuroMetrix develops and commercializes non-invasive medical devices to diagnose and treat pain and neurological disorders. The company has three commercial products. DPNCheck is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of entrapment neuropathies. Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.